Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood drug levels may predict side effects in skin cancer treatment

NCT ID NCT03610022

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 27 people with advanced basal cell skin cancer who were taking the drug vismodegib. The goal was to see if the amount of drug in their blood was linked to side effects like muscle cramps, hair loss, and taste changes. Researchers monitored patients for 6 months to gather this information, which may help doctors adjust doses to reduce side effects in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

27 people

The number who actually took part.

Started

Sep 2018

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib or patients who restarted treatment * 18 years-old or older * Complete medical record * Members or beneficiaries of a social security system, * Patients must have given informed consent, free and written. Exclusion Criteria: * Patients with or without BCC and not treated with vismodegib * BCC patients who stopped treatment with vismodegib due to non-response or progression on treatment * Patients under 18 years-old * Patients whose medical record is incomplete * Unaffiliated subjects or not beneficiaries of a security system social, * Patients who have not been informed and have not given their consent, free and written, * Pregnant and childbearing women without effective contraceptive method * Patients with confusional state

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced basal cell carcinoma Metastatic basal cell carcinoma

Contacts and locations

Locations

  • Chu de Bordeaux

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.